

The voltage-gated K⁺ channel Kv1.3 modulates platelet motility and $\alpha 2\beta 1$ integrin-dependent adhesion to collagen

Article

Published Version

Creative Commons: Attribution 4.0 (CC-BY)

Open Acces

Wright, J. R., Jones, S., Parvathy, S., Kaczmarek, L. K., Forsythe, I., Farndale, R. W., Gibbins, J. M. ORCID: <https://orcid.org/0000-0002-0372-5352> and Mahaut-Smith, M. P. (2022) The voltage-gated K⁺ channel Kv1.3 modulates platelet motility and $\alpha 2\beta 1$ integrin-dependent adhesion to collagen. *Platelets*, 33 (3). pp. 451-461. ISSN 0953-7104 doi: 10.1080/09537104.2021.1942818 Available at <https://centaur.reading.ac.uk/110260/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.1080/09537104.2021.1942818>

Publisher: Taylor & Francis

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online

ARTICLE



The voltage-gated K⁺ channel Kv1.3 modulates platelet motility and $\alpha_2\beta_1$ integrin-dependent adhesion to collagen

Joy R Wright^{1,2}, Sarah Jones^{2,3}, Sasikumar Parvathy⁴, Leonard K Kaczmarek⁵, Ian Forsythe⁶, Richard W Farndale⁷, Jonathan M Gibbins⁴, & Martyn P Mahaut-Smith²

¹Department of Cardiovascular Sciences, University of Leicester, Leicester, UK, ²Department of Molecular and Cell Biology, University of Leicester, Leicester, UK, ³Department of Life Sciences, Manchester Metropolitan University, Manchester, UK, ⁴Institute for Cardiovascular and Metabolic Research, University of Reading, Reading, UK, ⁵Department of Cellular and Molecular Physiology, Yale University School of Medicine, USA, ⁶Department of Neuroscience, Psychology and Behaviour, University of Leicester, Leicester, UK, and ⁷Department of Biochemistry, University of Cambridge, Cambridge, UK

Abstract

Kv1.3 is a voltage-gated K⁺-selective channel with roles in immunity, insulin-sensitivity, neuronal excitability and olfaction. Despite being one of the largest ionic conductances of the platelet surface membrane, its contribution to platelet function is poorly understood. Here we show that Kv1.3-deficient platelets display enhanced ADP-evoked platelet aggregation and secretion, and an increased surface expression of platelet integrin α_{IIb} . In contrast, platelet adhesion and thrombus formation *in vitro* under arterial shear conditions on surfaces coated with collagen were reduced for samples from Kv1.3^{-/-} compared to wild type mice. Use of collagen-mimetic peptides revealed a specific defect in the engagement with $\alpha_2\beta_1$. Kv1.3^{-/-} platelets developed significantly fewer, and shorter, filopodia than wild type platelets during adhesion to collagen fibrils. Kv1.3^{-/-} mice displayed no significant difference in thrombus formation within cremaster muscle arterioles using a laser-induced injury model, thus other pro-thrombotic pathways compensate *in vivo* for the adhesion defect observed *in vitro*. This may include the increased platelet counts of Kv1.3^{-/-} mice, due in part to a prolonged lifespan. The ability of Kv1.3 to modulate integrin-dependent platelet adhesion has important implications for understanding its contribution to normal physiological platelet function in addition to its reported roles in auto-immune diseases and thromboinflammatory models of stroke.

Introduction

Kv1.3 is a ubiquitously-expressed voltage-gated K⁺ channel with recognized roles in several physiological responses, including T cell activation, olfaction, and peripheral insulin sensitivity [1–3]. Furthermore, Kv1.3 inhibition has been proposed as a treatment for auto-immune diseases, obesity, neuroinflammation and other conditions [4–6]. In addition to its cell surface expression, this transmembrane protein is also located in the outer mitochondrial membrane where it has been linked to regulation of apoptosis and may therefore be a target for the treatment of cancer [7,8].

Voltage-gated potassium-selective channels displaying rapid activation and slow inactivation typical of Kv1.3 were first observed via patch clamp recordings in mammalian platelets by Maruyama[9]. Experiments in human platelets and murine megakaryocytes later demonstrated that these channels, encoded by

KCNA3, are responsible for setting the resting membrane potential of approximately –50 to –60 mV [10–12]. Subsequent reports using megakaryocytes from other mammalian species further support these conclusions [13–15]. Kv1.3^{-/-} mice demonstrate that loss of the channel reduces platelet agonist-evoked Ca²⁺ responses and increases the circulating platelet count [11,16]. However, major questions remain regarding the overall impact of Kv1.3 on platelet responses and the underlying mechanisms. Using Kv1.3-deficient mice and a range of *in vitro* and *in vivo* assays, we have explored the contribution of this voltage-gated channel to platelet function and lifespan. A key finding is that Kv1.3 contributes to collagen-dependent adhesion and motility through interaction with the integrin $\alpha_2\beta_1$. This advances our understanding of how Kv1.3 can contribute to function in platelets and other cell types, particularly within the immune system.

Methods

Reagents and antibodies

Antibodies for analysis of platelet surface antigens included FITC-conjugated rat anti-mouse GPIIb α (CD42b, Xia.G5), GPIIb β (CD42c, Xia.C3), GPV (CD42d, Gon.C2) and rat anti-mouse isotype control (P190-1) from Emfret Analytics (Eibelstadt, Germany). Antibodies against integrin chains

Correspondence: Martyn P Mahaut-Smith mpms1@leicester.ac.uk
Department of Molecular and Cell Biology, Henry Wellcome Building, University of Leicester, Leicester LE1 7RH, UK
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

were FITC-conjugated $\alpha 2$ (CD49b, Ha 1/29), α Ib (CD41, MWReg30), $\beta 1$ (CD29, Ha2/5), $\beta 3$ (CD61, 2 C9.G2) and isotype controls from BD Biosciences (Wokingham, UK). Platelet α -granule secretion was measured using anti-P-selectin-FITC (CD62P, Wug.E9) and IgG isotype control, (Emfret Analytics). Horm collagen (type I fibrils from equine tendon) was obtained from Alere (Stockport, Cheshire, UK) and the collagen peptides CRP-XL: crosslinked GCO(GPO)₁₀ GCOG-amide, VWF-III: GPC(GPP₅)GPRGQOGVMGFO (GPP₅)GPC-amide, and GFOGER: GPC(GPP₅)GFOGER (GPP₅)GPC-amide, were from CambCol Laboratories (Ely, Cambs, UK). Fibrinogen, 3,3' dihexyloxycarbocyanine iodide (DiOC₆), prostaglandin E (PGE₁), apyrase (type VII), ADP, and hirudin were all purchased from Sigma-Aldrich (Dorset, UK). FM@1-43 lipophilic styryl dye was from Molecular Probes (Life Technologies, Paisley, UK) and Phe-Pro-Arg-chloromethylketone (PPACK) from Hematologic Technologies Incorporated (Vermont, USA). DyLight® 649-conjugated anti-GPIIb antibody (Emfret Analytics) was used for *in vivo* thrombus formation experiments.

Animals and murine blood sampling

The generation of Kv1.3-deficient mice has been described previously[17]. These were backcrossed against C57BL/6 (Charles River, UK) and Kv1.3^{-/-} mice confirmed by genotyping (Figure 1). C57BL/6 mice matched for age and sex were purchased from Charles River, UK to represent wild-type (WT) controls. Experiments were carried out using mice of mixed gender. Blood was collected from the inferior vena cava of terminally isoflurane-anesthetised mice into 40 μ M PPACK for whole blood *in vitro* studies of platelet adhesion under conditions of arterial flow, or acid citrate dextrose (ACD; 85 mM trisodium citrate, 78 mM citric acid and 111 mM glucose) for all assays using washed platelets (described below). All procedures were carried out in accordance with local and Home Office guidelines and approved Institutional Animal Welfare Ethics Review Boards.

Preparation of washed platelets

Whole blood drawn into ACD was centrifuged at 300 g, 3 minutes, the platelet-rich plasma (PRP) removed and re-centrifuged at 200 g, 2 minutes to pellet remaining red blood cells. The platelet




Figure 1. **Platelet aggregation and secretion in wild type and Kv1.3^{-/-} mice.** (A,D) Representative traces of platelet aggregation in response to (A) 1 μ M ADP, and (D) 10 μ g/mL CRP-XL (black line, C57BL/6 WT and gray line, Kv1.3^{-/-} (note that the WT and Kv1.3^{-/-} aggregation traces completely overlap in D). (B, E) Mean percent peak aggregation of washed murine platelets in response to ADP (1 and 10 μ M, B) and CRP-XL (1 and 10 μ g/mL, E) is shown for WT (blue) and Kv1.3^{-/-} (red) mice (mean $\pm$ SEM, n = 5). (C, F) Platelet dense granule secretion measured by analysis of ATP release in response to ADP (1 and 10 μ M, C) and CRP-XL (1 and 10 μ g/mL, F). Values are the mean $\pm$ SEM, n = 5; *P < .05, **P < .01, ns = not significant. (G) Representative gel showing the genotyping of C57BL/6 WT, heterozygous, and Kv1.3^{-/-} mice. WT display 337-bp WT band only, Kv1.3^{-/-} display the 495-bp neomycin band only, and heterozygous mice display both bands. The numbers across the bottom of the lanes denote individual samples and controls: bp = base pairs, M = molecular marker, lanes numbered 1–6 contain samples from Kv1.3^{-/-} mice, followed by control samples from wild type (WT), heterozygous (HET) and Kv1.3^{-/-} (KO) mice; BLK = PCR negative control, and M = molecular marker.

suspension was supplemented with PGE₁ (100 ng/mL) and apyrase (0.32 U/mL), and centrifuged at 1000 g, 10 minutes. The platelet pellet was washed in normal platelet saline (NPS: 145 mM NaCl, 5 mM KCl, 1 mM MgCl₂, 10 mM D-glucose, 10 mM HEPES ~3.5 mM NaOH, pH 7.35) supplemented with 100 ng/mL PGE₁ and apyrase (0.32 U/mL), and following centrifugation at 1000 g, was resuspended to original volume in NPS, and platelets adjusted to a concentration of 4×10^8 /mL.

Flow cytometric analysis of platelet surface glycoproteins

Flow cytometry was used to measure the density of platelet surface glycoproteins. Washed platelets were diluted in NPS (1:10) and incubated for 15 minutes at room temperature with antibody or isotype control as per the manufacturer's protocol. Platelet suspensions were diluted a further 1:10 in 0.2% formylsaline and analyzed by flow cytometer (BD Facsanto II; BD Biosciences, Wokingham, UK), gating the platelet population initially by size (Forward Scatter, FSC) and granularity (Side Scatter, SSC), followed by detection of mean fluorescent intensity of each surface antigen. All flow cytometry data was analyzed using Kaluza software (Beckman Coulter). Note that the values are reported as arbitrary fluorescence units since the signal depends upon the instrument gain and sensitivity.

Aggregation and secretion studies

Turbidimetric measurement of platelet aggregation was performed using a model 400 lumi-aggregometer (Chronolog, Manchester, UK). Washed platelet suspensions were stirred for 3 minutes at 37°C, then fibrinogen (100 µg/mL), calcium chloride (2 mM) and agonist added (ADP or CRP-XL), and platelet aggregation recorded for 2 minutes. In parallel, ATP secretion from dense granules was measured using the CHRONO-LUME® luciferin; luciferase assay according to the manufacturer's guidelines.

Whole blood perfusion experiments

Whole blood was collected into 40 µM PPACK, and platelets loaded with 1 µM DiOC₆ for 20 minutes. Blood was perfused over coverslips coated with collagen (100 µg/mL), collagen peptide (100 µg/mL) or fibrinogen (200 µg/mL) at a shear rate of 1800 s⁻¹ for collagen and collagen peptides, and 800 s⁻¹ for fibrinogen. Thrombi were imaged by collection of a z-series of images acquired with an Olympus FV1000 confocal microscope at 3 separate fields per coverslip and analyzed in Image-J v1.49 (National Institutes of Health). Percent surface coverage, mean thrombus height and mean thrombus volume was calculated as described previously[18]. For study of platelet morphology, images of immobilized platelets were recorded at 30 minutes, and analyzed using Image-J.

Platelet motility studies

Washed platelets were incubated with FM®1-43 (5 µM) and exposed to collagen-coated coverslips for 30 minutes in the absence of flow, and platelet movement and adhesion recorded in real-time on an Olympus FV1000 confocal microscope (excitation of FM®1-43 at 488 nm and emission at 550–650 nm). All experiments used a 60x oil immersion lens (UPLSAPO 60x, NA 1.35). The Image-J Manual Tracking plug-in was used to track the movement of platelets from each genotype as they attached and responded to the collagen fibers.

In vivo thrombus formation

Thrombosis was measured in mouse cremaster arterioles as described previously[19]. Briefly, under general anesthesia the cremaster muscle was exteriorized and connective tissue removed. DyLight® 649-conjugated anti-GPIIb/IIIa antibody (0.2 µg/g mouse weight) was introduced into the carotid artery via a cannula. Injury to the vessel wall was made with a MicroPoint ablation laser (Andor Technology, Belfast, UK) and thrombus formation recorded using a digital camera with a charge-coupled device (C9300, Hamamatsu Photonics, Welwyn Garden City, UK). Data were analyzed using SlideBook 6 software (Intelligent Imaging Innovations, Denver, USA).

Platelet survival

To determine platelet lifespan, 500 µg of biotin (EZ-link Sulfo NHS-SS-biotin, Thermo Scientific, Paisley, UK) was injected into the tail vein on Day 1. On each subsequent day, 50 µl of blood was collected by tail bleed into ACD. Following centrifugation at 125 g for 10 minutes, PRP was incubated with 20 µl streptavidin-APC (BD Biosciences) for 40 minutes at room temperature in the dark. The sample was washed with NPS and centrifuged for 6 minutes at 860 g, and the platelet pellet resuspended in 0.2% formylsaline for analysis by flow cytometry.

Statistical analysis

All data and statistical analysis were performed using GraphPad Prism 6 (GraphPad Software, Inc, California, USA). Data are presented as mean ± SEM. For parametric data, comparison between 2 groups was performed using the Student *t* test and significance indicated as not significant (ns), **P* ≤ .05, ***P* ≤ .01 and ****P* ≤ .001.

Results

Expression of platelet surface glycoproteins

Deletion of Kv1.3 had no effect on expression of platelet surface glycoproteins GPIIb/IIIa, GPIIb/IIIa, GPV, and integrin subunits α₂, β₁ and β₃ (Table I). In contrast, integrin α_{IIb}β₃ was expressed at higher levels on platelets from Kv1.3^{-/-} compared to WT mice (*P* < .001). Since the α_{IIb} chain forms part of the α_{IIb}β₃ integrin complex, the main receptor for fibrinogen, we tested for possible differences in functional responses in which this major platelet adhesion ligand plays a key role, including aggregation, secretion and thrombus formation.

Kv1.3^{-/-} platelets exhibit enhanced ADP-evoked aggregation and secretion

Absence of Kv1.3 was shown to promote platelet aggregation and secretion following P2Y receptor activation with ADP, but not

Table I. Platelet surface glycoprotein expression in WT and Kv1.3^{-/-} mice.

	WT mice (MFI)	Kv1.3 ^{-/-} mice (MFI)	<i>P</i>
GPIIb/IIIa	14.48 ± 0.78	13.23 ± 0.95	.324
GPIIb/IIIa	5.26 ± 0.51	4.39 ± 0.41	.202
GPV	2.16 ± 0.18	1.96 ± 0.24	.504
α ₂	0.95 ± 0.03	0.95 ± 0.01	.894
β ₁	6.36 ± 0.19	6.45 ± 0.38	.844
α _{IIb}	4.82 ± 0.25	6.98 ± 0.44	<.001
β ₃	4.48 ± 0.12	4.63 ± 0.13	.438

Values minus the isotype control are given as the mean ± SEM. (n = 6–10).

MFI, mean fluorescent intensity (arbitrary units).

stimulation of GPVI with the collagen peptide, CRP-XL. Platelets from $Kv1.3^{-/-}$ mice displayed an elevated peak aggregation level in response to 1 μ M ADP ($P = .0395$; Figure 1A, B), and significantly increased secretion of ATP from dense granules at 1 and 10 μ M ADP ($P = .0193$; and $P = .0204$, respectively; Figure 1C). In contrast, aggregation and dense granule secretion were not significantly affected by loss of $Kv1.3$ in response to CRP-XL at either 1 μ g/mL or 10 μ g/mL (Figure 1D–F).

Adhesion to fibrinogen and collagen under flow conditions

Platelet adhesion to immobilized fibrinogen was not significantly different following perfusion of blood extracted from $Kv1.3^{-/-}$ compared to WT mice ($P = .1209$; Figure 2A, B). In contrast, flow-dependent platelet adhesion to fibrillar collagen was reduced in $Kv1.3$ -deficient platelets ($P = .0154$; Figure 2C, D). Platelet adhesion to collagen under conditions of high/elevated shear is dependent initially on the transient engagement of the platelet GPIb complex with immobilized VWF, which facilitates subsequent direct interaction of platelet collagen receptors $\alpha_2\beta_1$ and

GPVI with the collagen fibrils, enabling firm adhesion to take place [20,21]. Under conditions of shear *in vitro*, platelets perfused over surfaces coated with VWF alone exhibit a rolling across the surface with only brief transient attachment [22]. Therefore we used the triple-helical collagen mimetic peptide, VWF-III, in combination with either the $\alpha_2\beta_1$ -specific peptide, GFOGER, or the GPVI-specific peptide, CRP-XL to investigate the contribution of $Kv1.3$ to platelet adhesion via the two collagen receptors under flow conditions. Platelets from $Kv1.3^{-/-}$ mice had lower surface coverage on coverslips coated with VWF-III + GFOGER compared to platelets from WT mice ($P = .0239$; Figure 2E, F). In contrast, platelet surface coverage on coverslips coated with VWF-III + CRP-XL was not significantly different between the two genotypes ($P = .2235$; Figure 2G, H).

Morphology of platelets adhering to collagen peptides

Adherent platelets were classified into four morphological categories representing different stages of platelet adhesion and




Figure 2. Absence of $Kv1.3$ reduces integrin $\alpha_2\beta_1$ -dependent platelet adhesion to collagen. DiOC₆-labeled platelets in whole blood from WT or $Kv1.3^{-/-}$ mice were perfused over fibrinogen (200 μ g/mL) at a shear rate of 800 s^{-1} and collagen (100 μ g/mL) at 1800 s^{-1} . After 3 minutes of perfusion the coverslips were washed with normal platelet saline, and the images recorded and quantified as described in 'Methods.' Representative images (top panel) show platelet adhesion to fibrinogen (Figure 2A) and collagen (Figure 2C). Statistical analysis shows the percent of platelet surface adhesion (mean $\pm$ SEM) on fibrinogen (Figure 2B) and collagen (Figure 2D); ($n = 5$ for fibrinogen and 4 for collagen). DiOC₆-labeled platelets in whole blood from WT or $Kv1.3^{-/-}$ mice were also perfused at a shear rate of 1800 s^{-1} over coverslips coated with synthetic triple-helical peptides specific for the platelet collagen receptors integrin $\alpha_2\beta_1$ (GFOGER, 100 μ g/mL) and GPVI (CRP-XL, 100 μ g/mL). Representative images (lower panel) show platelet adhesion to (E) peptides VWF-III and GFOGER, and (G) peptides VWF-III and CRP-XL. Scale bar = 20 μ m. Statistical analysis shows the mean percent of platelet surface adhesion to (F) VWF-III and GFOGER ($n = 5$), and (H) VWF-III and CRP-XL ($n = 5$). (WT, blue; $Kv1.3^{-/-}$, red). * $P < .05$, ns = not significant.

activation[23]. Platelets that were rounded and without any protrusions, were classified as ‘round.’ Following initial adhesion, platelets begin to form protrusions to secure adhesion to the collagen fibrils, and these platelets were classified as ‘filopodia.’ Eventually, cytoskeletal remodeling allows actin fibers to fill between the filopodia, and platelets in this category were labeled as ‘ruffled’; and finally, depending on the matrix surface, platelets spread forming the typical ‘fried egg’ appearance.

Following perfusion over the collagen peptides VWF-III and GFOGER a trend toward fewer Kv1.3^{-/-} platelets reaching the ruffled stage was observed, although this failed to reach significance ($P = .0519$; Figure 3A), and there was no difference in the percentage of platelets at each stage of platelet adhesion following perfusion over VWF-III and CRP-XL (Figure 3D). Interestingly, despite a similar number of platelets extending filopodia for the two genotypes, deletion of Kv1.3 resulted in a significant reduction in the number of filopodia ($P = .0377$) and also filopodia length ($P = .003$) for platelets adhered to VWF-III and GFOGER (Figure 3C). Representative images for platelets attached to VWF-III and GFOGER are shown in Figure 3B and for VWF-III and CRP-XL in Figure 3E.

Motile responses of platelets adhering to collagen

To further assess the effect of the altered morphology of Kv1.3^{-/-} platelets during integrin $\alpha_2\beta_1$ -dependent platelet adhesion, the motile responses of WT and Kv1.3^{-/-} platelets were tracked during adhesion to fibrillar collagen under static conditions. The tracked trajectories of individual Kv1.3^{-/-} platelets traveled over a wider area than WT platelets (Figure 4A). Observation of video recordings of WT and Kv1.3^{-/-} platelet movement supported these findings of an altered Kv1.3^{-/-} platelet motile response to collagen. During initial attachment to collagen, platelets are able to extend long filopodia toward the collagen fibrils (Supplemental video 1). We observed that WT platelets (Supplemental video 2), rapidly extrude filopodia and pull on the collagen fibers to firmly adhere. In contrast, Kv1.3-deficient platelets displayed a loss of directional persistence, with fewer long filopodia and reduced pulling on collagen fibers (Supplemental video 3).

In vitro thrombus formation on collagen

The above experiments demonstrate that deletion of platelet Kv1.3 results in diminished responses involving integrin $\alpha_2\beta_1$, such as adhesion to collagen, but that $\alpha_{IIb}\beta_3$ -dependent functions, such as aggregation, are not reduced. This suggests that Kv1.3^{-/-} platelets




Figure 3. Kv1.3-deficient platelets form fewer and shorter filopodia during integrin $\alpha_2\beta_1$ -dependent adhesion. Platelet morphology following perfusion over collagen peptides at a shear rate of 1800 s^{-1} , was classified as ‘round’ (round platelet with no protrusions), ‘filopodia’ (protrusions securing collagen fibrils), ‘ruffled’ (lamellipodia formation), and ‘spread’ (flattened or fried egg appearance). Distribution of platelet morphology following perfusion of WT and Kv1.3^{-/-} platelets over (A) VWF-III and GFOGER (100 $\mu\text{g}/\text{mL}$ each peptide), and (D) VWF-III and CRP-XL (100 $\mu\text{g}/\text{mL}$ each peptide). Data is expressed as the mean percent of platelets in each category ($n = 5$). Representative images of WT and Kv1.3^{-/-} platelet morphology on each peptide surface (B) VWF-III and GFOGER, and (E) VWF-III and CRP-XL. Scale bar = 10 μm . (C, F) Data shows the filopodia number per platelet (based on 50 platelets per treatment group), and filopodia length (μm)(based on length of 100 filopodia per treatment group) of WT and Kv1.3^{-/-} platelets adhered to (C) VWF-III and GFOGER, and (F) VWF-III and CRP-XL. * $P < .05$, *** $P < .005$.




Figure 4. Kv1.3-deficient platelets lack directional persistence during adhesion to collagen via $\alpha_2\beta_1$. The morphology and motile responses of murine platelets labelled with FM@1-43 lipophilic styryl dye (5 μ M) were tracked during adhesion to collagen (100 μ g/mL) under static conditions. The plotting of co-ordinates tracked the trajectories of WT and Kv1.3-deficient platelets during platelet attachment to the collagen fibers. Platelet movement and direction is measured by displacement (μ m) along the x and y axis. Data from 3 independent experiments.

should be able to aggregate and form thrombi where platelet attachment to collagen has been successful. Following platelet perfusion over collagen at a shear rate of 1800 s^{-1} , Kv1.3-deficient platelets that did successfully adhere to collagen fibrils were able to form thrombi, but with significantly reduced height ($P = .0254$; Figure 5A), and volume ($P = .0254$; Figure 5B). The difference between thrombi formed by WT and Kv1.3^{-/-} platelets on fibrillar collagen can also be seen in the side elevation of z-stack fluorescent images in Figure 5C.

Characterization of platelet function in vivo: thrombus formation

To investigate whether the altered *in vitro* responses of Kv1.3^{-/-} platelets translate into a change in function within the circulation, we studied thrombus formation in the cremaster muscle arterioles of anaesthetised male mice using the laser-induced injury model [24–26]. The profile of median thrombus fluorescence ($n = 20$ thrombi in five WT mice and 25 thrombi in five Kv1.3^{-/-} mice) through the 500 second duration of thrombus growth and regression in Kv1.3-deficient mice was not significantly different from thrombi formed in WT mice (Figure 5E). Consistent with this, maximum thrombus fluorescence was not altered (Figure 5D).

Platelet size and platelet lifespan

Kv1.3-deficient mice display elevated platelet counts, but no change in megakaryocyte development within the marrow [11]. To explore whether an altered lifespan could account for this phenotype, we measured platelet clearance in Kv1.3^{-/-} and WT mice using an *in vivo* biotinylation approach [27]. The percent biotinylated platelets was significantly elevated above that measured in the platelet population from WT mice at 72 hours ($P = .006$) and at 96 hours ($P = .0452$) post biotin injection (Figure 6A), suggesting that an enhanced lifespan may contribute

to the greater platelet count observed in Kv1.3^{-/-} mice. Kv1.3^{-/-} platelets were no different in size ($P = .1979$; Figure 6B), or granularity ($P = .198$; Figure 6C), as determined by Forward and Side Scatter using flow cytometry.

Discussion

Kv1.3 plays a crucial role in maintaining the resting membrane potential in platelets [10,11], regulating entry of the key second messenger Ca^{2+} ; however, its contribution to hemostasis and thrombosis is less clear. The present study provides new evidence that loss of Kv1.3 in murine platelets modulates a number of platelet responses, particularly collagen-evoked adhesion and motile responses through a mechanism dependent on integrin $\alpha_2\beta_1$.

Platelet adhesion and thrombus formation relies on two key integrins, namely $\alpha_2\beta_1$ which binds to collagen, and $\alpha_{IIb}\beta_3$ which binds several ligands including fibrinogen, fibronectin, Von Willebrand factor (VWF), and fibrin [28]. Our studies of murine platelet adhesion under conditions of arterial shear demonstrate that adhesion to fibrillar collagen, where $\alpha_2\beta_1$ is an important adhesive receptor, is significantly impaired following deletion of Kv1.3. In contrast, loss of Kv1.3 had no effect on $\alpha_{IIb}\beta_3$ -dependent platelet binding to immobilized fibrinogen. This specific role for Kv1.3 in $\alpha_2\beta_1$ -mediated adhesion was further demonstrated in experiments using combinations of triple-helical collagen-specific peptides. Kv1.3^{-/-} platelet adherence was significantly reduced compared to those from WT mice when perfused over surfaces coated with a combination of VWF-III, a peptide which contains the VWF-A3 collagen binding motif, and the integrin $\alpha_2\beta_1$ -specific peptide, GFOGER. In contrast, no phenotypic difference was observed between adhesion of WT and Kv1.3^{-/-} platelets perfused over surfaces coated with VWF-III combined with the GPVI-specific collagen peptide, CRP-XL. This is consistent with experiments using human platelets, where Pugh and colleagues used integrin-specific peptides of differing affinity to show that $\alpha_2\beta_1$ enhances the rate of recruitment of platelets to a collagenous surface [29].

Exposure to collagen induces marked changes in platelet morphology. Initial events involve the extension of filopodial protrusions which allow attachment to collagen fibers, followed by formation of actin-rich lamellipodia and eventual transformation to the typical ‘fried egg’ appearance during platelet spreading [23,30]. Mutations that affect the molecular mechanisms and protein interactions of cytoskeletal reorganization during platelet shape change impair the ability of platelets to adhere and form a thrombus [31–34]. Our studies of DiOC₆-loaded platelets demonstrate that in the absence of Kv1.3^{-/-}, fewer platelets progress to form lamellipodia (ruffled appearance) on $\alpha_2\beta_1$ -dependent surfaces coated with VWF-III/GFOGER; furthermore, Kv1.3^{-/-} platelets exhibited shorter and fewer filopodia compared to WT controls. Video recordings under static conditions show that WT platelets extend long filopodia toward collagen fibers, pulling the fibers upon initial attachment, before spreading (Supplementary video 1 and 2), whereas platelets lacking Kv1.3 are less able to facilitate attachment (Supplementary video 3). Subsequent tracking of the trajectories of individual platelet movement under the same conditions further demonstrated that Kv1.3^{-/-} platelet haptotaxis toward collagen is less efficient, with platelets traveling over a wider area, appearing to have less ability to ‘sense’ the collagen or maintain directional persistence toward it. This is consistent with weaker integrin-dependent adhesion permitting greater motility, as shown in HT1080 fibrosarcoma haptotaxis experiments [35]. Interestingly, blockade or reduced expression of Kv1.3 also impairs migration of T-lymphocytes [36,37], and alters detection of electrical fields in neutrophils




Figure 5. **Absence of Kv1.3 reduces *in vitro*, but not *in vivo*, thrombus formation.** DiOC₆-loaded platelets from Kv1.3^{-/-} mice were perfused over collagen-coated coverslips (100 μg/mL), and analyzed for (A) total thrombus volume (μm³) and (B) thrombus height (μm). Data shown is the mean ± SEM for thrombi formed by platelets from WT (blue) and Kv1.3^{-/-} mice (red) (n = 4; *P < .05). (C) Representative side elevation of z-stack fluorescent images of thrombi formed on fibrillar collagen by platelets from WT (upper image) and Kv1.3^{-/-} (lower image) mice. (D) Mean integrated fluorescence (arbitrary units), and (E) Plot of median fluorescence intensity (arbitrary units) over time (seconds), during *in vivo* thrombus formation following laser-induced injury in cremaster muscle arterioles of WT and Kv1.3^{-/-} mice; (n = 20 thrombi in 5 WT mice and 25 thrombi in 5 Kv1.3^{-/-} mice).




Figure 6. **Platelets from Kv1.3^{-/-} display a longer lifespan.** (A) Assessment of platelet lifespan was carried out using *in vivo* biotinylation of murine platelets, recording the percent of biotinylated platelets isolated from WT and Kv1.3^{-/-} mice over five days (n = 4 for each genotype). Flow cytometric analysis of (B) platelet size and (C) platelet granularity gating on forward scatter and side scatter of platelet populations isolated from WT and Kv1.3^{-/-} mice (n = 8). Data shown is mean ± SEM. **P < .01, *P < .05, ns not significant.

[38]. Voltage-gated sodium channels (Na_v) have also been proposed to contribute to cellular motility and migration in several types of immune cells including lymphocytes [39] and macrophages [40] and intracellularly localized $\text{Na}_v1.6$ supports invasiveness of human breast cancer cells [41]. Sodium channel β subunits are crucial components of the mechanism whereby pore-forming α subunits $\text{Na}_v1.5$ or 1.6 regulate adhesion and migration and there is evidence that $\text{Na}_v\beta_1$ can act independently as a cell adhesion molecule [42–44].

Thrombus formation by DiOC₆-labeled $\text{Kv}1.3^{-/-}$ platelets is inhibited during perfusion over collagen-coated surfaces. Our results suggest that this may be due to a $\text{Kv}1.3$ -associated contribution to the formation of platelet filopodia and their mechanosensing ability to detect collagen fibrils in the microenvironment, rather than a defect in platelet aggregation. Surprisingly, however, we saw no difference in thrombus formation or thrombus size in cremaster muscle arterioles of WT or $\text{Kv}1.3^{-/-}$ mice following laser injury using an *in vivo* model that causes endothelial damage and collagen exposure [45]. A similar lack of arterial thrombosis phenotype in $\text{Kv}1.3^{-/-}$ mice has also recently been reported using alternative models of thrombosis which depend more upon activation by collagen than the laser injury model used in the present study [16]. Therefore, the lack of $\text{Kv}1.3$ is compensated for *in vivo* by other pathways. The enhanced aggregation and secretion that we observed *in vitro* with ADP in $\text{Kv}1.3^{-/-}$ platelets may explain this compensation. We observed increased α_{IIb} integrin expression on the surface, however β_3 subunit expression was not altered. It is possible that the α_{IIb} subunit is expressed on the surface independently of associated beta subunits; this is known to happen for other integrin subunits [46]. In its monomeric form it would not contribute to enhanced aggregation unless it can combine with other beta subunits, which requires further study. Although Fan and colleagues [16] have observed an upregulation in expression of KCNQ4 and other K^+ channels in $\text{Kv}1.3^{-/-}$ platelets, we observed no direct evidence for such a change in our previous electrophysiological recordings [11]. It is known that secondary activation of P2Y₁₂ receptors by released ADP amplifies collagen-evoked platelet aggregation [47,48]. Thus, the enhanced ADP responses in $\text{Kv}1.3$ -deficient platelets may contribute to the lack of significant difference in collagen-evoked aggregation in standard stirred suspension. Given this argument, the reduced thrombus formation under arterial shear is somewhat unexpected. However, the altered motile responses to collagen may be the overriding determinant of whether the platelets initially attach and therefore can generate a thrombus.

We previously reported increased platelet count in $\text{Kv}1.3^{-/-}$ mice which was not due to an altered frequency or size of bone marrow MKs [11]. Here we show that significantly higher numbers of biotinylated platelets remained in the circulation of $\text{Kv}1.3^{-/-}$ mice post-injection compared to WT. Platelet lifespan in the mouse is around 5 days, and is regulated by components of the intrinsic apoptotic pathway, whereby the pro-survival protein family member, Bcl-xL controls the activity of pro-apoptotic proteins Bak and Bax [49,50]. Studies in lymphocytes have identified $\text{Kv}1.3$ on the inner mitochondrial membrane [51], where it plays a role in the induction of apoptosis through its interaction with Bax [52,53]. Further study is needed to confirm the possible existence and potential contribution of mito $\text{Kv}1.3$ to platelet apoptosis, but it is possible that platelet apoptosis is impaired when Bax cannot interact with mito $\text{Kv}1.3$. This potential role for $\text{Kv}1.3$ in platelet production, and pro-survival phenotype in the absence of $\text{Kv}1.3$, may contribute to elevated levels of platelets in the circulation of the $\text{Kv}1.3^{-/-}$ mice. The recent study by Fan and colleagues [16] confirmed the increased platelet count phenotype of $\text{Kv}1.3^{-/-}$ mice, without a change in marrow megakaryopoiesis,

and additionally demonstrated increased numbers of megakaryocytes in the spleen. This organ is an alternative site of platelet production in the mouse as well as a site of platelet clearance, and thus may also contribute to the increased platelet count following $\text{Kv}1.3$ deletion. The elevated megakaryopoiesis and reduced clearance is likely to increase the number of reticulated platelets in the circulation, which are known to be more reactive than mature platelets [54,55], and this may partially explain the enhanced aggregation and secretory response to low concentrations of ADP in $\text{Kv}1.3^{-/-}$ platelets. Although Fan and colleagues [16] concur with a lack of *in vivo* thrombus formation phenotype of $\text{Kv}1.3^{-/-}$ mice, they report that aggregation of platelets to several agonists *in vitro*, including thrombin and collagen, and high dose ADP (20 μM), are reduced by loss of channel function following either genetic deletion or application of a pore-blocking antibody (6E12#15) [16]. The difference between the two studies requires further investigation but may result from variability in the method of preparing platelets for *in vitro* studies.

The experiments reported here raise a number of key questions that we have not been able to investigate due to the impact of the COVID-19 pandemic on our laboratories. This challenge has been recognized by Journal editorial policies [56] and we report here the completed aspects to the work which highlight the need for additional studies. Future experiments should investigate the mechanism responsible for enhanced ADP-evoked aggregation and secretion in $\text{Kv}1.3^{-/-}$ platelets and whether responses to other G-protein-coupled receptor agonists are affected. We also propose a pharmacological approach using blockers such as margatoxin and Pap-1. A key area to investigate is the mechanism by which $\text{Kv}1.3$ modulates integrin function and motility; particularly important questions are whether channel opening is required and whether there is an involvement of the K^+ channel regulatory proteins identified in our platelet ion channel transcriptome study [12]. The effect of $\text{Kv}1.3$ deletion on interactions with other adhesive substrates is worthwhile investigating, which would benefit from more advanced imaging approaches. Given the enhanced platelet lifespan and increased platelet number in $\text{Kv}1.3$ -deficient mice, additional studies should also investigate the presence of mito $\text{Kv}1.3$ and its potential role in the platelet.

Although platelets are highly specialized for hemostasis, they also contribute to immune responses, often serving as a link between the hemostatic and inflammatory systems [57–60]. For example, they facilitate the phagocytic removal and sequestering of pathogens [61–63] and release antimicrobial agents and chemokines [64,65]. $\text{Kv}1.3$ has a well established role in immune function, particularly in T-lymphocytes [66–68] and its overexpression is a common feature of chronic inflammatory diseases, contributing to the over-reaction of cellular immunity and subsequent cytokine storm [69,70]. Interestingly, in a study using the middle cerebral artery occlusion model, a model of ischemic stroke that involves the formation of occlusive platelet thrombi in response to combined thrombotic and inflammatory stimuli [71], the selective $\text{Kv}1.3$ blocker Pap-1 dose-dependently reduced the infarct area in rodents, reducing microglial activation and improving neuronal survival [72]. In light of the present study and work by Fan and colleagues [16], it is worthwhile exploring the relative contribution of platelet $\text{Kv}1.3$ to the etiology of immune disorders.

Key points

- The voltage-gated K^+ channel $\text{Kv}1.3$ enhances collagen-evoked platelet adhesion and thrombus formation through an $\alpha_2\beta_1$ integrin-dependent mechanism

- Kv1.3-deficient platelets display reduced filopodia formation and greater motility during attachment to collagen fibres

Acknowledgements

The authors acknowledge the contribution of staff in the Division of Biomedical Services, Preclinical Research Facility, University of Leicester, for technical support and care of experimental animals. We also thank Lory Francescut for excellent technical support, including genotyping. The work was funded by grants from the British Heart Foundation (PG/11/56 and PG/15/21/31355).

Disclosure statement

R.W.F. is Chief Scientific Officer of CambCol Laboratories. Other authors declare no conflict of interest.

Funding

This work was supported by the British Heart Foundation [PG/11/56, PG/15/21/31355].

Authorship contributions

J.R.W. designed and performed experiments, collected and analysed data, and wrote the manuscript; S.J. performed and analysed the aggregation and secretion experiments; P.S. performed and analysed the *in vivo* thrombus studies; L.K.K. kindly provided the Kv1.3^{-/-} mice for the study; I.F. advised on the breeding and genotyping of the mouse colonies and edited the manuscript; R.W.F. provided the collagen peptides and edited the manuscript; J.M.G. supervised the *in vivo* thrombus experiments and edited the manuscript; and M.P.M.-S. designed the study, supervised experiments, interpreted data, and wrote the manuscript.

Supplementary material

Supplemental data for this article can be accessed on the [publisher's website](#).

ORCID

Jonathan M Gibbins  <http://orcid.org/0000-0002-0372-5352>

References

- Fadool DA, Tucker JM, Perkins R, Fasciani G, Thompson RN, Parsons AD, Overton KM, Koni PA, Flavell RA, Kaczmarek LK, et al. Kv1.3 channel gene-targeted deletion produces "Super-Smeller Mice" with altered glomeruli, interacting scaffolding proteins, and biophysics. *Neuron* 2004;41(3):389–404. doi:10.1016/S0896-6273(03)00844-4.
- Xu J, Wang P, Li Y, Li G, Kaczmarek LK, Wu Y, Koni PA, Flavell RA, Desir GV. The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity. *Proc Natl Acad Sci U S A* 2004;101(9):3112–3117. doi:10.1073/pnas.0308450100.
- Cahalan MD, Chandy KG. The functional network of ion channels in T lymphocytes. *Immunol Rev* 2009;231(1):59–87.
- Upadhyay SK, Eckel-Mahan KL, Mirbolooki MR, Tjong I, Griffey SM, Schmunk G, Koehne A, Halbout B, Iadonato S, Pedersen B, et al. Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance. *Proc Natl Acad Sci U S A* 2013;110(24):E2239–E2248. doi:10.1073/pnas.1221061110.
- Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. *Proc Natl Acad Sci U S A* 2006;103(46):17414–17419. doi:10.1073/pnas.0605136103.
- Sarkar S, Nguyen HM, Malovic E, Luo J, Langley M, Palanisamy BN, Singh N, Manne S, Neal M, Gabrielle M, et al. Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinson's disease. *J Clin Invest* 2020;130(8):4195–4212. doi:10.1172/JCI136174.
- Leanza L, Henry B, Sassi N, Zoratti M, Chandy KG, Gulbins E, Szabó I. Inhibitors of mitochondrial Kv1.3 channels induce Bax/Bak-independent death of cancer cells. *EMBO Mol Med* 2012;4(7):577–593. doi:10.1002/emmm.201200235.
- Teisseyre A, Palko-Labuz A, Sroda-Pomianek K, Michalak K. Voltage-gated potassium channel Kv1.3 as a target in therapy of cancer. *Front Oncol* 2019;9:933. doi:10.3389/fonc.2019.00933.
- Maruyama Y. A patch-clamp study of mammalian platelets and their voltage-gated potassium current. *J Physiol* 1987;391:467–485. doi:10.1113/jphysiol.1987.sp016750.
- Mahaut-Smith MP, Rink TJ, Collins SC, Sage SO. Voltage-gated potassium channels and the control of membrane potential in human platelets. *J Physiol* 1990;428(1):723–735. doi:10.1113/jphysiol.1990.sp018237.
- McCloskey C, Jones S, Amisten S, Snowden RT, Kaczmarek LK, Erlinge D, Goodall AH, Forsythe ID, Mahaut-Smith MP. Kv1.3 is the exclusive voltage-gated K⁺ channel of platelets and megakaryocytes: roles in membrane potential, Ca²⁺ signalling and platelet count. *J Physiol* 2010;588(Pt 9):1399–1406. doi:10.1113/jphysiol.2010.188136.
- Wright JR, Amisten S, Goodall AH, Mahaut-Smith MP. Transcriptomic analysis of the ion channelome of human platelets and megakaryocytic cell lines. *Thromb Haemost* 2016;116(2):272–284. doi:10.1160/TH15-11-0891.
- Kawa K. Voltage-gated calcium and potassium currents in megakaryocytes dissociated from guinea-pig bone marrow. *J Physiol* 1990;431(1):187–206. doi:10.1113/jphysiol.1990.sp018326.
- Romero E, Sullivan R. Complexity of the outward K⁺ current of the rat megakaryocyte. *Am J Physiol* 1997;272(5 Pt 1):C1525–C1531. doi:10.1152/ajpcell.1997.272.5.C1525.
- Kapural L, Feinstein MB, O'Rourke F, Fein A. Suppression of the delayed rectifier type of voltage gated K⁺ outward current in megakaryocytes from patients with myelogenous leukemias. *Blood* 1995;86(3):1043–1055. doi:10.1182/blood.V86.3.1043.1043.
- Fan C, Yang X, Wang WW, Wang J, Li W, Guo M, Huang S, Wang Z, Liu K. Role of Kv1.3 channels in platelet functions and thrombus formation. *Arterioscler Thromb Vasc Biol* 2020;40(10):2360–2375. doi:10.1161/ATVBAHA.120.314278.
- Koni PA, Khanna R, Chang MC, Tang MD, Kaczmarek LK, Schlichter LC, Flavell RA. Compensatory anion currents in Kv1.3 channel-deficient thymocytes. *J Biol Chem* 2003;278(41):39443–39451. doi:10.1074/jbc.M304879200.
- Pugh N, Simpson AM, Smethurst PA, de Groot PG, Raynal N, Farndale RW. Synergism between platelet collagen receptors defined using receptor-specific collagen-mimetic peptide substrata in flowing blood. *Blood* 2010;115(24):5069–5079. doi:10.1182/blood-2010-01-260778.
- Sahli K, Flora GD, Sasikumar P, Maghrabi AH, Holbrook LM, AlOuda SK, Elghezawy A, Sage T, Stainer AR, Adiyaman R, et al. Structural, functional and mechanistic insights uncover the fundamental role of orphan Connexin62 in platelets. *Blood* 2021;137(6):830–843. doi:10.1182/blood.2019004575.
- Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. *Circ Res* 2007;100(12):1673–1685. doi:10.1161/01.RES.0000267878.97021.ab.
- Farndale RW. Collagen-induced platelet activation. *Blood Cells Mol Dis* 2006;36(2):162–165. doi:10.1016/j.bcmd.2005.12.016.
- McEver RP, Zhu C. Rolling cell adhesion. *Annu Rev Cell Dev Biol* 2010;26(1):363–396. doi:10.1146/annurev.cellbio.042308.113238.
- Aslan JE, McCarty OJ. Rho GTPases in platelet function. *J Thromb Haemost* 2013;11(1):35–46. doi:10.1111/jth.12051.
- Rosen ED, Raymond S, Zollman A, Noria F, Sandoval-Cooper M, Shulman A, Merz JL, Castellino FJ. Laser-induced noninvasive vascular injury models in mice generate platelet- and coagulation-dependent thrombi. *Am J Pathol* 2001;158(5):1613–1622. doi:10.1016/S0002-9440(10)64117-X.
- Celi A, Merrill-Skoloff G, Gross P, Falati S, Sim DS, Flaumenhaft R, Furie BC, Furie B. Thrombus formation: direct real-time observation and digital analysis of thrombus assembly in a living mouse by confocal and widefield intravital microscopy. *J Thromb Haemost* 2003;1(1):60–68. doi:10.1046/j.1538-7836.2003.t01-1-00033.x.
- Falati S, Gross PL, Merrill-Skoloff G, Sim D, Flaumenhaft R, Celi A, Furie BC, Furie B. In vivo models of platelet function and thrombosis: study of real-time thrombus formation. *Methods Mol Biol* 2004;272:187–197. doi:10.1385/1-59259-782-3:187.
- Josefsson EC, White MJ, Dowling MR, Kile BT. Platelet life span and apoptosis. *Methods Mol Biol* 2012;788:59–71.

28. Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. *Blood* 2004;104(6):1606–1615. doi:10.1182/blood-2004-04-1257.
29. Pugh N, Bihan D, Perry DJ, Farndale RW. Dynamic analysis of platelet deposition to resolve platelet adhesion receptor activity in whole blood at arterial shear rate. *Platelets* 2015;26(3):216–219. doi:10.3109/09537104.2014.893289.
30. Lickert S, Sorrentino S, Studt JD, Medalia O, Vogel V, Schoen I. Morphometric analysis of spread platelets identifies integrin α IIb β 3-specific contractile phenotype. *Sci Rep* 2018;8(1):5428. doi:10.1038/s41598-018-23684-w.
31. McCarty OJ, Larson MK, Auger JM, Kalia N, Atkinson BT, Pearce AC, Ruf S, Henderson RB, Tybulewicz VLJ, Machesky LM, et al. Rac1 is essential for platelet lamellipodia formation and aggregate stability under flow. *J Biol Chem* 2005;280(47):39474–39484. doi:10.1074/jbc.M504672200.
32. Akbar H, Shang X, Perveen R, Berryman M, Funk K, Johnson JF, Tandon NN, Zheng Y. Gene targeting implicates Cdc42 GTPase in GPVI and non-GPVI mediated platelet filopodia formation, secretion and aggregation. *PLoS One* 2011;6(7):e22117. doi:10.1371/journal.pone.0022117.
33. Barkalow KL, Falet H, Italiano JE Jr., van Vugt A, Carpenter CL, Schreiber AD, Hartwig JH. Role for phosphoinositide 3-kinase in Fc gamma RIIA-induced platelet shape change. *Am J Physiol Cell Physiol* 2003;285(4):C797–805. doi:10.1152/ajpcell.00165.2003.
34. Pleines I, Hagedorn I, Gupta S, May F, Chakarova L, van Hengel J, Offermanns S, Krohne G, Kleinschnitz C, Brakebusch C, et al. Megakaryocyte-specific RhoA deficiency causes macrothrombocytopenia and defective platelet activation in hemostasis and thrombosis. *Blood* 2012;119(4):1054–1063. doi:10.1182/blood-2011-08-372193.
35. Farndale RW, Lisman T, Bihan D, Hamaia S, Smerling C, Pugh N, Konitsiotis A, Leitinger B, de Groot P, Jarvis G, et al. Cell-collagen interactions: the use of peptide Toolkits to investigate collagen-receptor interactions. *Biochem Soc Trans* 2008;36(Pt 2):241–250. doi:10.1042/BST0360241.
36. Levite M, Cahalon L, Peretz A, HersHKoviz R, Sobko A, Ariel A, Desai R, Attali B, Lider O. Extracellular K(+) and opening of voltage-gated potassium channels activate T cell integrin function: physical and functional association between Kv1.3 channels and beta1 integrins. *J Exp Med* 2000;191(7):1167–1176. doi:10.1084/jem.191.7.1167.
37. Matheu MP, Beeton C, Garcia A, Chi V, Rangaraju S, Safrina O, Monaghan K, Uemura MI, Li D, Pal S, et al. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. *Immunity* 2008;29(4):602–614. doi:10.1016/j.immuni.2008.07.015.
38. Kindzelskii AL, Petty HR. Ion channel clustering enhances weak electric field detection by neutrophils: apparent roles of SKF96365-sensitive cation channels and myeloperoxidase trafficking in cellular responses. *Eur Biophys J* 2005;35(1):1–26. doi:10.1007/s00249-005-0001-2.
39. Fraser SP, Diss JK, Lloyd LJ, Pani F, Chioni A-M, George AJT, Djamgoz MBA. T-lymphocyte invasiveness: control by voltage-gated Na⁺ channel activity. *FEBS Lett* 2004;569(1–3):191–194. doi:10.1016/j.febslet.2004.05.063.
40. Carrithers MD, Chatterjee G, Carrithers LM, Offoha R, Iheagwara U, Rahner C, Graham M, Waxman SG. Regulation of podosome formation in macrophages by a splice variant of the sodium channel SCN8A. *J Biol Chem* 2009;284(12):8114–8126. doi:10.1074/jbc.M801892200.
41. Fraser SP, Diss JK, Chioni AM, Mycielska ME, Pan H, Yamaci RF, Pani F, Siwy Z, Krasowska M, Grzywna Z, et al. Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. *Clin Cancer Res* 2005;11(15):5381–5389. doi:10.1158/1078-0432.CCR-05-0327.
42. Brackenbury WJ, Calhoun JD, Chen C, Miyazaki H, Nukina N, Oyama F, Ranscht B, Isom LL. Functional reciprocity between Na⁺ channel Nav1.6 and β 1 subunits in the coordinated regulation of excitability and neurite outgrowth. *Proc Natl Acad Sci U S A* 2010;107(5):2283–2288. doi:10.1073/pnas.0909434107.
43. Chioni AM, Brackenbury WJ, Calhoun JD, Isom LL, Djamgoz MB. A novel adhesion molecule in human breast cancer cells: voltage-gated Na⁺ channel beta1 subunit. *Int J Biochem Cell Biol* 2009;41(5):1216–1227. doi:10.1016/j.biocel.2008.11.001.
44. Davis TH, Chen C, Isom LL. Sodium channel beta1 subunits promote neurite outgrowth in cerebellar granule neurons. *J Biol Chem* 2004;279(49):51424–51432. doi:10.1074/jbc.M410830200.
45. Sasikumar P, AlOuda KS, Kaiser WJ, Holbrook LM, Kriek N, Unsworth AJ, Bye AP, Sage T, Ushioda R, Nagata K, et al. The chaperone protein HSP47: a platelet collagen binding protein that contributes to thrombosis and hemostasis. *J Thromb Haemost* 2018;16(5):946–959. doi:10.1111/jth.13998.
46. Solovjov DA, Pluskota E, Plow EF. Distinct roles for the alpha and beta subunits in the functions of integrin α IIb β 3. *J Biol Chem* 2005;280(2):1336–1345. doi:10.1074/jbc.M406968200.
47. Watson SP. Platelet activation by extracellular matrix proteins in haemostasis and thrombosis. *Curr Pharm Des* 2009;15(12):1358–1372. doi:10.2174/138161209787846702.
48. Hechler B, Gachet C. P2 receptors and platelet function. *Purinergic Signal* 2011;7(3):293–303. doi:10.1007/s11302-011-9247-6.
49. Mason KD, Carpinelli MR, Fletcher JJ, Collinge JE, Hilton AA, Ellis S, Kelly PN, Ekert PG, Metcalf D, Roberts AW, et al. Programmed anuclear cell death delimits platelet life span. *Cell* 2007;128(6):1173–1186. doi:10.1016/j.cell.2007.01.037.
50. Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR, Iciek LA, Morgan SJ, Nasarre MC, Nelson R, et al. Bcl-2 family proteins are essential for platelet survival. *Cell Death Differ* 2007;14(5):943–951. doi:10.1038/sj.cdd.4402081.
51. Szabo I, Bock J, Jekle A, Soddemann M, Adams C, Lang F, Zoratti M, Gulbins E. A novel potassium channel in lymphocyte mitochondria. *J Biol Chem* 2005;280(13):12790–12798. doi:10.1074/jbc.M413548200.
52. Szabo I, Bock J, Grassme H, Soddemann M, Wilker B, Lang F, Zoratti M, Gulbins E. Mitochondrial potassium channel Kv1.3 mediates Bax-induced apoptosis in lymphocytes. *Proc Natl Acad Sci U S A* 2008;105(39):14861–14866. doi:10.1073/pnas.0804236105.
53. Gulbins E, Sassi N, Grassme H, Zoratti M, Szabo I. Role of Kv1.3 mitochondrial potassium channel in apoptotic signalling in lymphocytes. *Biochim Biophys Acta* 2010;1797(6–7):1251–1259. doi:10.1016/j.bbabo.2010.01.018.
54. Ault KA, Rinder HM, Mitchell J, Carmody MB, Vary CP, Hillman RS. The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis. *Am J Clin Pathol* 1992;98(6):637–646. doi:10.1093/ajcp/98.6.637.
55. Lakkis N, Dokainish H, Abuzahra M, Tsyboulev V, Jorgensen J, Ponce De Leon A, Saleem A. Reticulated platelets in acute coronary syndrome: a marker of platelet activity. *J Am Coll Cardiol* 2004;44(10):2091–2093. doi:10.1016/j.jacc.2004.05.033.
56. Watson SP, Harrison P, Halford GM. Editorial policy during the lockdown. *Platelets* 2020;31(4):411. doi:10.1080/09537104.2020.1758532.
57. Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet-neutrophil interactions: linking hemostasis and inflammation. *Blood Rev* 2007;21(2):99–111. doi:10.1016/j.blre.2006.06.001.
58. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. *Circ Res* 2007;100(1):27–40. doi:10.1161/01.RES.0000252802.25497.b7.
59. Vieira-de-Abreu A, Campbell RA, Weyrich AS, Zimmerman GA. Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum. *Semin Immunopathol* 2012;34(1):5–30.
60. Jenne CN, Urrutia R, Kubes P. Platelets: bridging hemostasis, inflammation, and immunity. *Int J Lab Hematol* 2013;35(3):254–261. doi:10.1111/jlth.12084.
61. Yeaman MR. The role of platelets in antimicrobial host defense. *Clin Infect Dis* 1997;25(5):951–968; quiz 969–970. doi:10.1086/516120.
62. Fitzgerald JR, Foster TJ, Cox D. The interaction of bacterial pathogens with platelets. *Nat Rev Microbiol* 2006;4(6):445–457. doi:10.1038/nrmicro1425.

63. Gaertner F, Ahmad Z, Rosenberger G, Fan S, Nicolai L, Busch B, Yavuz G, Luckner M, Ishikawa-Ankerhold H, Hennel R, et al. Migrating platelets are mechano-scavengers that collect and bundle bacteria. *Cell* **2017**;171(6):1368–1382 e1323. doi:[10.1016/j.cell.2017.11.001](https://doi.org/10.1016/j.cell.2017.11.001).
64. Yeaman MR, Bayer AS. Antimicrobial peptides from platelets. *Drug Resist Updat* **1999**;2(2):116–126. doi:[10.1054/drup.1999.0069](https://doi.org/10.1054/drup.1999.0069).
65. Semple JW, Italiano JE Jr., Freedman J. Platelets and the immune continuum. *Nat Rev Immunol* **2011**;11(4):264–274. doi:[10.1038/nri2956](https://doi.org/10.1038/nri2956).
66. DeCoursey TE, Chandy KG, Gupta S, Cahalan MD. Voltage-gated K⁺ channels in human T lymphocytes: a role in mitogenesis? *Nature* **1984**;307(5950):465–468. doi:[10.1038/307465a0](https://doi.org/10.1038/307465a0).
67. Wulff H, Pennington M. Targeting effector memory T-cells with Kv1.3 blockers. *Curr Opin Drug Discov Devel* **2007**;10(4):438–445.
68. Feske S, Wulff H, Skolnik EY. Ion channels in innate and adaptive immunity. *Annu Rev Immunol* **2015**;33(1):291–353. doi:[10.1146/annurev-immunol-032414-112212](https://doi.org/10.1146/annurev-immunol-032414-112212).
69. Kazama I, Tamada T, Tachi M. Usefulness of targeting lymphocyte Kv1.3-channels in the treatment of respiratory diseases. *Inflamm Res* **2015**;64(10):753–765. doi:[10.1007/s00011-015-0855-4](https://doi.org/10.1007/s00011-015-0855-4).
70. Chandy KG, Norton RS. Peptide blockers of Kv1.3 channels in T cells as therapeutics for autoimmune disease. *Curr Opin Chem Biol* **2017**;38:97–107. doi:[10.1016/j.cbpa.2017.02.015](https://doi.org/10.1016/j.cbpa.2017.02.015).
71. Braeuninger S, Kleinschütz C, Nieswandt B, Stoll G. Focal cerebral ischemia. *Methods Mol Biol* **2012**;788:29–42.
72. Chen YJ, Nguyen HM, Maezawa I, Jin LW, Wulff H. Inhibition of the potassium channel Kv1.3 reduces infarction and inflammation in ischemic stroke. *Ann Clin Transl Neurol* **2018**;5(2):147–161. doi:[10.1002/acn3.513](https://doi.org/10.1002/acn3.513).